[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599171":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":43,"centralContacts":56,"locations":62,"responsibleParty":84,"collaborators":43,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":43,"eligibilityCriteria":91,"healthyVolunteers":88,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":43,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":43,"overallStatus":65,"whyStopped":43,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Shanghai Junshi Bioscience Co., Ltd.","OTHER",[8,14,19,24,29,33],{"label":9,"type":10,"description":11,"interventionNames":12},"DLBCL-Gemox","EXPERIMENTAL","In participants with relapsed\u002Frefractory diffuse large B cell lymphoma ineligible for ASCT",[13],"Drug: JS203 in combination with gemcitabine and oxaliplatin",{"label":15,"type":10,"description":16,"interventionNames":17},"DLBCL-ICE","In participants with relapsed\u002Frefractory diffuse large B cell lymphoma intended for ASCT",[18],"Drug: JS203 in combination with ifosfamide, carboplatin and etoposide",{"label":20,"type":10,"description":21,"interventionNames":22},"DLBCL- RCHOP","In participants with newly diagnosed diffuse large B cell lymphoma",[23],"Drug: JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone",{"label":25,"type":10,"description":26,"interventionNames":27},"FL-Lena","In participants with relapsed\u002Frefractory follicular lymphoma",[28],"Drug: JS203 combined with lenalidomide",{"label":30,"type":10,"description":31,"interventionNames":32},"MCL-Lena","In participants with relapsed\u002Frefractory mantle cell lymphoma",[28],{"label":34,"type":10,"description":35,"interventionNames":36},"MZL-Lena","In participants with relapsed\u002Frefractory marginal zone lymphoma",[28],[38,44,48,52],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","JS203 in combination with gemcitabine and oxaliplatin","Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days\u002Fcycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.",[9],null,{"type":39,"name":45,"description":46,"armGroupLabels":47,"otherNames":43},"JS203 in combination with ifosfamide, carboplatin and etoposide","Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.",[15],{"type":39,"name":49,"description":50,"armGroupLabels":51,"otherNames":43},"JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days\u002Fcycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.",[20],{"type":39,"name":53,"description":54,"armGroupLabels":55,"otherNames":43},"JS203 combined with lenalidomide","lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days\u002Fcycle) QW, Cycle 2 to Cycle 12 (28 days\u002Fcycle) Q4W.",[25,30,34],[57],{"name":58,"role":59,"phone":60,"phoneExt":43,"email":61},"Bang.an Peng, Master","CONTACT","13526844722","bang.an_peng@junshipharma.com",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":72,"coordinates":73},"Point",[74,75],116.39723,39.9075,{"lat":75,"lon":74},[78,82],{"name":79,"role":59,"phone":80,"phoneExt":43,"email":81},"Yuqin Song, Ph.D","010-88196118","SongYQ_VIP@163.com",{"name":79,"role":83,"phone":43,"phoneExt":43,"email":43},"PRINCIPAL_INVESTIGATOR",{"type":85,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100599171","phase-2-js203-combination-regimens-in-b-cell-non-hodgkins-lymphoma-100599171",false,"NCT07081022","JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be enrolled：\n\n* Age range: 18 to 80 years old (inclusive), both male and female are acceptable；\n* ECOG: 0-2；\n* B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；\n* At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；\n\nExclusion Criteria:\n\n* A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；\n* Previously received CD20-CD3 bispecific antibody treatment；\n* Previous allogeneic hematopoietic stem cell transplantation；\n* Previous solid organ transplantation；\n* History of autoimmune diseases；\n* Patients with a history of macrophage activation syndrome (MAS)\u002F hemophagocytic lymphohistiocytosis (HLH)；\n* Patients with a history of progressive multifocal leukoencephalopathy (PML)；\n* A known or suspected history of CNS lymphoma (including primary or secondary)；\n* There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；","ALL","18 Years","80 Years",{"count":96,"type":97},180,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma",[103],"B-cell Non-Hodgkin's Lymphoma","2025-08-20",{"date":106,"type":107},"2025-08-21","ACTUAL",{"date":109,"type":107},"2025-08-17",{"date":111,"type":97},"2027-04-06",{"name":5,"class":6},1]